Lv4
468 积分 2024-07-03 加入
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
11天前
已完结
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
11天前
已完结
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers
21天前
已完结
Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance
1个月前
已完结
Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients’ Clinical Features
1个月前
已关闭
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2− Breast Cancers
1个月前
已完结
PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
5个月前
已完结
177Lu-Labeled Antibody–Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors
6个月前
已完结
Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2
6个月前
已完结
89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
6个月前
已完结
皖公网安备34019202002308
